News articles about Compugen (NASDAQ:CGEN) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Compugen earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.5952354146572 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Compugen Ltd. (CGEN) Reaches $4.30 After 8.00% Up Move; Last … – MTA Star (mtastar.com)
- Analyzing Compugen (CGEN) and Ionis Pharmaceuticals (IONS) (americanbankingnews.com)
- Compugen Ltd. (CGEN) – Lookout Watch List stock – Wall Street Morning (wallstreetmorning.com)
- Compugen Ltd. (CGEN) look forward to -13.50% EPS growth for next year – Wallstreet Investorplace (wallstreetinvestorplace.com)
Compugen (CGEN) opened at $4.45 on Thursday. The firm has a market cap of $220.56, a price-to-earnings ratio of -6.04 and a beta of 0.30. Compugen has a 52-week low of $2.25 and a 52-week high of $5.40.
A number of brokerages have recently weighed in on CGEN. Zacks Investment Research cut shares of Compugen from a “hold” rating to a “sell” rating in a research report on Monday, February 26th. ValuEngine cut shares of Compugen from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th.
Compugen Company Profile
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.